Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck, Allergan Suggested As Suitors But Biogen's Attractiveness Under Question

Executive Summary

Biogen's share price has risen on speculation that it is an acquisition target for Merck & Co and Allergan. But with a number of uncertainties hanging over the company, can Biogen negotiate a premium price?


Related Content

Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Allergan Sees Growth From New Launches, Not Big M&A
Stockwatch: Teva, Biogen, Ionis, Sage And The Art Of Strategic News Placement
Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment
Scangos Leaves Biogen Transformed And Transitioning


Related Companies